Stock Quote Notification for Eli Lilly and Company

Eli Lilly and sent this email to their subscribers on December 13, 2024.

Company: Eli Lilly and Company
Ticker: LLY
Exchange: NYSE
Last Trade: $789.12
Change: 6.77
% Change: +0.87%
Volume: 3,058,269
Day's High: $794.25
Day's Low: $772.99
Previous Close: $782.35

Text-only version of this email

Eli Lilly and Company Company: Eli Lilly and Company Ticker: LLY Exchange: NYSE Last Trade: $789.12 Change: 6.77 % Change: +0.87% Volume: 3,058,269 Day's High: $794.25 Day's Low: $772.99 Previous Close: $782.35

Show all

The Latest Emails Sent By Eli Lilly and

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

New Form 8-K for Eli Lilly and Company

New Form 8-K for Eli Lilly and Company

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance

More Emails, Deals & Coupons From Eli Lilly and

Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease

Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease

Lilly expands manufacturing footprint in Ireland with $1.8 billion investment

Lilly expands manufacturing footprint in Ireland with $1.8 billion investment

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Weekly Summary Alert for Eli Lilly and Company

Weekly Summary Alert for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose

Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis

New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis